Drug Landscape ›
FERRIC AMMONIUM CITRATE ›
Regulatory · United States
Marketing authorisation
FDA
Safety signals — FAERS
Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.
Window: 20 April 2025 – 20 April 2026
Total reports: 44
Most-reported reactions
Anaemia — 6 reports (13.64%) Death — 6 reports (13.64%) Lower Respiratory Tract Infection — 5 reports (11.36%) Cytomegalovirus Chorioretinitis — 4 reports (9.09%) Drug Hypersensitivity — 4 reports (9.09%) Extrapulmonary Tuberculosis — 4 reports (9.09%) Hiv Peripheral Neuropathy — 4 reports (9.09%) Pulmonary Tuberculosis — 4 reports (9.09%) Virologic Failure — 4 reports (9.09%) Drug Ineffective — 3 reports (6.82%)
Source database →
FERRIC AMMONIUM CITRATE in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Frequently asked questions
Is FERRIC AMMONIUM CITRATE approved in United States?
Yes. FDA has authorised it.
Who is the marketing authorisation holder for FERRIC AMMONIUM CITRATE in United States?
Marketing authorisation holder not available in our data.